331 related articles for article (PubMed ID: 31223078)
1. Reviewing Biochemical Implications of Normal and Mutated Huntingtin in Huntington's Disease.
Tellone E; Galtieri A; Ficarra S
Curr Med Chem; 2020; 27(31):5137-5158. PubMed ID: 31223078
[TBL] [Abstract][Full Text] [Related]
2. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
[TBL] [Abstract][Full Text] [Related]
3. Differential distribution of the normal and mutated forms of huntingtin in the human brain.
Gourfinkel-An I; Cancel G; Trottier Y; Devys D; Tora L; Lutz Y; Imbert G; Saudou F; Stevanin G; Agid Y; Brice A; Mandel JL; Hirsch EC
Ann Neurol; 1997 Nov; 42(5):712-9. PubMed ID: 9392570
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
5. The pathobiology of perturbed mutant huntingtin protein-protein interactions in Huntington's disease.
Wanker EE; Ast A; Schindler F; Trepte P; Schnoegl S
J Neurochem; 2019 Nov; 151(4):507-519. PubMed ID: 31418858
[TBL] [Abstract][Full Text] [Related]
6. Huntingtin and its role in neuronal degeneration.
Li SH; Li XJ
Neuroscientist; 2004 Oct; 10(5):467-75. PubMed ID: 15359012
[TBL] [Abstract][Full Text] [Related]
7. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z
Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099
[TBL] [Abstract][Full Text] [Related]
8. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
9. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
[TBL] [Abstract][Full Text] [Related]
10. Pathological polyQ expansion does not alter the conformation of the Huntingtin-HAP40 complex.
Huang B; Guo Q; Niedermeier ML; Cheng J; Engler T; Maurer M; Pautsch A; Baumeister W; Stengel F; Kochanek S; Fernández-Busnadiego R
Structure; 2021 Aug; 29(8):804-809.e5. PubMed ID: 33909994
[TBL] [Abstract][Full Text] [Related]
11. Cancer: From Wild-Type to Mutant Huntingtin.
Thion MS; Humbert S
J Huntingtons Dis; 2018; 7(3):201-208. PubMed ID: 29889077
[TBL] [Abstract][Full Text] [Related]
12. Loss-of-Huntingtin in Medial and Lateral Ganglionic Lineages Differentially Disrupts Regional Interneuron and Projection Neuron Subtypes and Promotes Huntington's Disease-Associated Behavioral, Cellular, and Pathological Hallmarks.
Mehler MF; Petronglo JR; Arteaga-Bracho EE; Gulinello ME; Winchester ML; Pichamoorthy N; Young SK; DeJesus CD; Ishtiaq H; Gokhan S; Molero AE
J Neurosci; 2019 Mar; 39(10):1892-1909. PubMed ID: 30626701
[TBL] [Abstract][Full Text] [Related]
13. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
[TBL] [Abstract][Full Text] [Related]
14. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
[TBL] [Abstract][Full Text] [Related]
15. How does the Huntington's disease mutation damage cells?
Rubinsztein DC
Sci Aging Knowledge Environ; 2003 Sep; 2003(37):PE26. PubMed ID: 13679594
[TBL] [Abstract][Full Text] [Related]
16. Degradation of misfolded proteins by autophagy: is it a strategy for Huntington's disease treatment?
Lin F; Qin ZH
J Huntingtons Dis; 2013; 2(2):149-57. PubMed ID: 25063512
[TBL] [Abstract][Full Text] [Related]
17. Neurobiology of Huntington's Disease.
De Souza RA; Leavitt BR
Curr Top Behav Neurosci; 2015; 22():81-100. PubMed ID: 25205327
[TBL] [Abstract][Full Text] [Related]
18. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation.
Träger U; Andre R; Lahiri N; Magnusson-Lind A; Weiss A; Grueninger S; McKinnon C; Sirinathsinghji E; Kahlon S; Pfister EL; Moser R; Hummerich H; Antoniou M; Bates GP; Luthi-Carter R; Lowdell MW; Björkqvist M; Ostroff GR; Aronin N; Tabrizi SJ
Brain; 2014 Mar; 137(Pt 3):819-33. PubMed ID: 24459107
[TBL] [Abstract][Full Text] [Related]
19. Mutant huntingtin can paradoxically protect neurons from death.
Zuchner T; Brundin P
Cell Death Differ; 2008 Mar; 15(3):435-42. PubMed ID: 17975550
[TBL] [Abstract][Full Text] [Related]
20. The P42 peptide and Peptide-based therapies for Huntington's disease.
Marelli C; Maschat F
Orphanet J Rare Dis; 2016 Mar; 11():24. PubMed ID: 26984770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
